Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bismuth-amoxicillin-vonoprazan Triple Therapy vs Bismuth Quadruple Therapy in First-line Anti-Helicobacter Pylori Treatment
NCT07358130Recruiting
- Sponsor
- Kaohsiung Medical University
- Start
- Oct 2025
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vonoprazan in Helicobacter pylori infection (2 arms), sponsored by Kaohsiung Medical University. Primary endpoints: Rate of Helicobacter pylori eradication at 6 weeks and Evaluation of the safety of Helicobacter pylori eradication therapy at 14 days. Started Oct 2025; status: recruiting.
02
Drugs
vonoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT07358130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07358130.